Nanobiotix raises €25.1 million in private placement

Nanobiotix SA, which is developing technology for enhancing radiotherapy treatments, has raised €25.1 million in a private share placement to finance its portfolio and the expected European market launch of its lead product NBTXR3.

Full text available to subscribers only. Click here for information on subscribing to MedNous.